Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
Status:
Completed
Trial end date:
2020-12-12
Target enrollment:
Participant gender:
Summary
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on
structural studies and multiple alignment analysis. By comparing the positive-stranded RNA
genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal
nucleotide analogue to repurpose for COVID-19 treatment